论文部分内容阅读
目的探讨比索洛尔对慢性阻塞性肺疾病患者肺功能及相关炎症介质的影响。方法选择2014年7月—2015年8月就诊的慢性阻塞性肺疾病患者120例,随机分为观察组和对照组各60例。对照组给予羧甲司坦片0.5 mg/次口服,3次/d。观察组在对照组治疗基础上给予比索洛尔1.25 mg/次口服,1次/d。两组患者均治疗12周,分别在治疗前后检测两组肺功能,第1秒用力呼气容积(forced expiratory volume in one second,FEV1)、FEV1占用力肺活量百分比(FEV1/FVC)、FEV1占预计值的百分比(FEV1%pred);检测炎症介质,白细胞介素(interleukin,IL)6、IL-8、肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)。计量资料比较采用t检验,P<0.05为差异有统计学意义。结果治疗后观察组FEV1由(1.16±0.18)L提高到(1.48±0.31)L,FEV1/FVC由(48.4±9.8)%升高到(58.3±10.7)%,FEV1%pred由(49.3±11.8)%提高到(56.9±12.6)%,对照组FEV1由(1.14±0.19)L提高到(1.28±0.26)L,FEV1/FVC由(48.5±9.7)%升高到(51.1±11.2)%,FEV1%pred由(49.4±11.7)%提高到(50.6±12.5)%。观察组FEV1、FEV1/FVC、FEV1%比对照组改善更明显,比较差异有统计学意义(均P<0.05)。治疗后,观察组IL-6由(0.36±0.25)μg/L下降到(0.13±0.10)μg/L,IL-8由(0.73±0.57)μg/L下降到(0.45±0.36)μg/L,TNF-α由(0.86±0.29)μg/L下降到(0.56±0.08)μg/L,对照组IL-6由(0.34±0.29)μg/L下降到(0.25±0.16)μg/L,IL-8由(0.75±0.55)μg/L下降到(0.65±0.43)μg/L,TNF-α由(0.84±0.27)μg/L下降到(0.72±0.25)μg/L。治疗后观察组IL-6、IL-8、TNF-α与对照组比较差异有统计学意义(均P<0.05)。结论比索洛尔能有效改善慢性阻塞性肺疾病患者肺功能,降低炎症介质水平。
Objective To investigate the effect of bisoprolol on pulmonary function and related inflammatory mediators in patients with chronic obstructive pulmonary disease. Methods A total of 120 chronic obstructive pulmonary disease patients from July 2014 to August 2015 were randomly divided into observation group (60 cases) and control group (60 cases). The control group was given carbocisteine tablets 0.5 mg / orally, 3 times / d. The observation group was given bisoprolol 1.25 mg / time orally once a day on the basis of the control group. Two groups of patients were treated for 12 weeks. Before and after treatment, the pulmonary function, forced expiratory volume in one second (FEV1), FEV1 (FEV1 / FVC) and FEV1 (FEV1% pred). The inflammatory mediators, interleukin (IL) 6, IL-8 and tumor necrosis factor-α (TNF-α) were detected. Measurement data were compared using t test, P <0.05 for the difference was statistically significant. Results After treatment, the FEV1 increased from (1.16 ± 0.18) L to (1.48 ± 0.31) L, the FEV1 / FVC increased from (48.4 ± 9.8)% to (58.3 ± 10.7)% and the FEV1% pred from (49.3 ± 11.8 (FEV1 / FVC) increased from (48.5 ± 9.7)% to (51.1 ± 11.2)% in control group from (1.14 ± 0.19) L to (1.28 ± 0.26) FEV1% pred increased from (49.4 ± 11.7)% to (50.6 ± 12.5)%. The improvement of FEV1, FEV1 / FVC and FEV1% in the observation group was more obvious than that in the control group, with significant difference (all P <0.05). After treatment, IL-6 in the observation group decreased from (0.36 ± 0.25) μg / L to (0.13 ± 0.10) μg / L and from 0.73 ± 0.57 μg / L to (0.45 ± 0.36) μg / L IL-6 in control group decreased from (0.34 ± 0.29) μg / L to (0.25 ± 0.16) μg / L, IL-6 decreased from 0.86 ± 0.29 μg / L to 0.56 ± 0.08 μg / -8 decreased from (0.75 ± 0.55) μg / L to (0.65 ± 0.43) μg / L, while TNF-α decreased from (0.84 ± 0.27) μg / L to (0.72 ± 0.25) μg / L. After treatment, the levels of IL-6, IL-8 and TNF-α in the observation group were significantly different from those in the control group (all P <0.05). Conclusion Bisoprolol can effectively improve lung function and reduce the level of inflammatory mediators in patients with chronic obstructive pulmonary disease.